Pure autonomic failure

Enterin announces FDA acceptance of an investigator sponsored IND to treat a patient with prodromal multisystem atrophy (MSA) with ENT-01

Retrieved on: 
Wednesday, May 31, 2023
Pure autonomic failure, ATP13A2, Central nervous system, University, PD, Diarrhea, Rotenone, DSM-IV codes, Constipation, CMO, Cell, Life expectancy, Vomiting, Dementia, Oxidative stress, Investigational New Drug, Patient, MSA, Alpha-synuclein, Nausea, Entrepreneurship, Erectile dysfunction, FDA, GI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Disease, Pharmaceutical industry, Dietary supplement, Parkinsonism

Treatment will continue indefinitely or until significant adverse events occur that warrant discontinuation of drug.

Key Points: 
  • Treatment will continue indefinitely or until significant adverse events occur that warrant discontinuation of drug.
  • Individuals diagnosed with MSA have an average life expectancy of 6-8 years and there is no existing treatment which halts the progression of the disease.
  • Phase 3 studies in Parkinson’s disease-related constipation and further Phase 2 studies in Parkinson’s disease-related psychosis and dementia are being planned.
  • On the basis of these symptoms, he has been diagnosed as having prodromal MSA.

A little-understood sleep disorder affects millions and has clear links to dementia – 4 questions answered

Retrieved on: 
Saturday, May 27, 2023
Blood pressure, Smell, Pure autonomic failure, Association, Conversation, Melatonin, Tremor, RBD, Rapid eye movement sleep behavior disorder, Respiratory rate, Sleep, Deficit spending, Narcolepsy, Constipation, Quality of life, Multiple system atrophy, Brain, Research, Disorder, DSM-IV codes, Injury, Dementia, Clonazepam, Parkinsonism, Dream, Patient, Sleep disorder, Risk, Lewy body, Diagnosis, Erectile dysfunction, Obstructive sleep apnea, Color, Synucleinopathy, Disease, REM, Pharmaceutical industry

The disorder, known as REM sleep behavior disorder, or RBD in the medical field, affects around 1% of the general population worldwide and about 2% of adults over 65.

Key Points: 
  • The disorder, known as REM sleep behavior disorder, or RBD in the medical field, affects around 1% of the general population worldwide and about 2% of adults over 65.
  • The Conversation talked with Anelyssa D'Abreu, a neurologist who specializes in geriatric neurology, to explain what researchers know about the condition’s links to dementia.

1. What is REM sleep behavior disorder?

    • REM sleep only comprises 20% to 25% of total sleep, but its proportion increases throughout the night.
    • But someone with REM sleep behavior disorder will act out their dreams.
    • Appropriate testing, including a sleep study, are needed to determine if a patient has REM sleep behavior disorder, as opposed to another disorder, such as obstructive sleep apnea.
    • REM sleep behavior disorder can occur at any age, but symptoms usually start with people in their 40s and 50s.

2. What causes REM sleep behavior disorder?

    • In some cases of REM sleep behavior disorder, a clear cause cannot be identified.
    • In both situations, REM sleep behavior disorder may be associated with synucleinopathies, a group of neurodegenerative disorders in which aggregates of the protein α-synuclein accumulate in brain cells.
    • REM sleep behavior disorder may precede these diseases or occur at any time during the disease process.

3. What are the links between the sleep disorder and dementia?

    • REM sleep behavior disorder may be the first symptom of Parkinson’s disease or dementia with Lewy bodies.
    • After 12 years, 73.5% of those with REM sleep behavior disorder had developed a related neurodegenerative disorder.
    • REM sleep behavior disorder may also be observed in other neurodegenerative disorders such as Alzheimer’s disease and Huntington’s disease, but at much lower rates.

4. Does an early diagnosis help?

    • RBD, in that scenario, is an early sign of those disorders.
    • At this time, there are no approved therapies to prevent the onset of these neurodegenerative diseases in those with REM sleep behavior disorder.
    • We also recommend measures to avoid injury, such as removing breakable objects from the room, protecting windows and padding floors.

CND Life Sciences Partners with Soleo Health to Broaden the Awareness and Availability of CND's Cutaneous Neurodiagnostic Tests

Retrieved on: 
Thursday, November 3, 2022
Blood pressure, Media, URAC, Digestion, Education, Neurology, Research, NIA, Perspiration, Partnership, Neuromuscular Disorders, Neurodegeneration, Solution, Autonomic neuropathy, Company, Practitioner, LLC, Synucleinopathy, Pharmacy, National, Dementia, Dysautonomia, NINDS, CND, Pure autonomic failure, Diagnosis, Sleep, Patient, Leadership, Lewy body, SBIR, ACHC, Heart rate, Distinction, Rapid eye movement sleep behavior disorder, Family, Physician, REM, Parkinson's disease, Multiple system atrophy, NIH, Movement disorders, Joint Commission, Health, Medicine, MD, Management, Pharmaceutical industry, Public relations, Stroke, PHOENIX, Ageing

PHOENIX and FRISCO, Texas , Nov. 3, 2022 /PRNewswire/ -- CND Life Sciences (http://cndlifesciences.com), an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, is pleased to announce its strategic collaboration with Soleo Health®, a leading national provider of complex specialty pharmacy services, to educate neuromuscular specialists and other neurologists on CND's novel Syn-One Test® and its intraepidermal nerve fiber density assay called Small-Fiber Dx™.

Key Points: 
  • "We are in an era of medicine where precision diagnostics have become increasingly crucial to optimize patient care," said Rick Morello, CND Life Sciences' Chief Executive Officer.
  • "We are quite pleased to work with Soleo Health as a key partner to help CND educate neurologists who could benefit most from incorporating Syn-One and other cutaneous neurodiagnostics into their practice."
  • We are grateful that Soleo Health will help CND educate clinicians on the Syn-One Test and how it can be used effectively in patient care."
  • Additionally, Soleo Health operates more than 40 infusion centers throughout the U.S.
    Visit www.soleohealth.com or connect with Soleo Health on LinkedIn , Facebook and Twitter for more information.

Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System

Retrieved on: 
Wednesday, November 2, 2022
American Autonomic Society, AAS, Center, Clinical trial, Parkinson's disease, Autonomic nervous system, Biopharma LLC, NASDAQ, Company, Pure autonomic failure, Autonomic, Patient, Multiple system atrophy, Noh, International Symposium on Endovascular Therapy, 2021 Essex County Council election, Drug development, Bachelor of Medicine, Bachelor of Surgery, LS, Quality of life, Beth Israel Deaconess Medical Center, Orthostatic hypotension, MSA, Caregiver burden, Pharmaceutical industry, Hydraulic machinery, Neurology

DUBLIN, Nov. 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc.("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today will present new ampreloxetine data in neurogenic orthostatic hypotension (nOH) from the Company's Phase 3 program at the 33rd International Symposium on the Autonomic Nervous System, a meeting of the American Autonomic Society (AAS).

Key Points: 
  • DUBLIN, Nov. 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc.("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today will present new ampreloxetine data in neurogenic orthostatic hypotension (nOH) from the Company's Phase 3 program at the 33rd International Symposium on the Autonomic Nervous System, a meeting of the American Autonomic Society (AAS).
  • Ampreloxetine is an investigational, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic nOH in patients with multiple system atrophy (MSA).
  • "These ampreloxetine data are encouraging for patients with MSA suffering with neurogenic orthostatic hypotension.
  • MSA is a progressive brain disorder that affects movement and balance and disrupts the function of the autonomic nervous system.

CND Life Sciences Awarded Third NIH SBIR Grant to Study the Syn-One Test® in Patients Diagnosed with REM Sleep Behavior Disorder (RBD)

Retrieved on: 
Thursday, October 6, 2022
Lewy body, National Institute, Movement, Risk, PD, REM, Diagnosis, Neurodegeneration, Patient, MSA, Behavioural sciences, Sleep, Government budget balance, National Institute of Neurological Disorders and Stroke, Parkinson's disease, Research, NIH, Lists of diseases, CND, National Institute on Aging, NIA, Dementia, Synucleinopathy, SBIR, Psychiatry, MD, Pure autonomic failure, NAPS, AI, RBD, National, Neurology, PAF, Multiple system atrophy, DLB, Alpha-synuclein, Gold, Stanford University, Dysautonomia, Radical behaviorism, Stroke, Rapid eye movement sleep behavior disorder, Movement disorders, Pathology, Pharmaceutical industry, Medical imaging

PHOENIX, Oct. 6, 2022 /PRNewswire/ -- CND Life Sciences, an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, has been awarded a $3 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH). This is the third NIH SBIR Phase II award for the company to study and advance the clinical application of the Syn-One Test, the only commercially available test that uses skin biopsies to help clinicians diagnose a synucleinopathy, a family of neurodegenerative diseases that includes Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), pure autonomic failure (PAF) and REM sleep behavior disorder (RBD).

Key Points: 
  • Patients diagnosed with RBD experience vivid, often disruptive dreams associated with simple or complex motor behavior during the REM phase of sleep.
  • The success of future treatments for these disorders will be tied to how precisely and early we can understand the patient's pathology," explained Levine.
  • Founded in 2017, CND Life Sciences is dedicated to supporting the care of patients facing the potential diagnosis of a neurodegenerative disease and other neurological conditions.
  • The company has research collaborations with multiple biopharmaceutical companies and has been awarded three prestigious NIH SBIR grants to advance the validation and clinical utility of its Syn-One Test.

CND Life Sciences Awarded NIH SBIR Grant to Study Novel Skin Biopsy Test for Dementias

Retrieved on: 
Wednesday, May 18, 2022
Interim, Dementia, Risk, Lewy body, Disease, Parkinson's disease, Lists of diseases, Research, Multiple system atrophy, Neurodegeneration, NIA, National Institute, Patient, Gold, Health, CND, SBIR, Rapid eye movement sleep behavior disorder, DLB, Movement disorders, MCI, Caregiver, REM, Sleep, NIH, Government budget balance, Stroke, Frustration, National Institute of Neurological Disorders and Stroke, Alzheimer's disease, State, Lewy Body Dementia Association, Neurology, Dysautonomia, Pure autonomic failure, National Institute on Aging, National, Movement, LBDA, Diagnosis, MD, Synucleinopathy, Pharmaceutical industry

PHOENIX, May 18, 2022 /PRNewswire/ -- CND Life Sciences, an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, has been awarded a $2.4 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH). This is the second NIH SBIR Phase II award for the company to study and advance the application of the Syn-One Test, the only commercially available test that uses skin biopsies to help clinicians distinguish between serious neurologic disorders, such as dementia with Lewy bodies (DLB) and Alzheimer's disease.

Key Points: 
  • "Understanding the type of dementia that is developing early in the disease course is becoming increasingly important, as novel drug therapies and other treatment interventions are finally becoming a reality."
  • This lack of diagnostic certainty can lead to unnecessary tests, frustration by patients and caregivers, and suboptimal care.
  • Founded in 2017, CND Life Sciences is dedicated to supporting the care of patients facing the potential diagnosis of a neurodegenerative disease and other neurological conditions.
  • The company has research collaborations with multiple biopharmaceutical companies and in 2020 was awarded a previous NIH SBIR award to advance the validation and clinical utility of its Syn-One Test.

CND LIFE SCIENCES ADDS TWO ACCOMPLISHED PATHOLOGISTS TO LEADERSHIP TEAM

Retrieved on: 
Thursday, March 24, 2022
Dementia, Pure autonomic failure, National, Organization, Neurodegeneration, Children's Hospital Los Angeles, Synucleinopathy, Diagnosis, Lists of diseases, Growth, CND, Skin, New York University Grossman School of Medicine, Stroke, Research, University of California, Irvine, Pathology, Lewy body, National Institute, Parkinson's disease, Medical director, Marie Cassidy, Ventana Medical Systems, MD, University, Technology, NIH, Human, Multiple system atrophy, UC, Physician, National Institute of Neurological Disorders and Stroke, Genetics, UCLA, Tulane University, Patient, Medical device, Medicine, Medical imaging, Pharmaceutical industry, Medicine, Science

PHOENIX, March 24, 2022 /PRNewswire/ -- CND Life Sciences, Inc. (www.cndlifesciences.com), an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, has added two senior pathologists to its core team, Dr. Janine Feng, MD and Dr. Dana Haydel, MD.

Key Points: 
  • Prior to starting at CND, she worked as a pathologist at Roche Tissue Diagnostics (formerly Ventana Medical Systems) for 17 years.
  • "CND is the first commercial laboratory to offer a test that detects synucleinopathies in the skin," said Dr. Feng.
  • "We are thrilled to welcome these accomplished pathologists to our team and are confident that their expertise will be key to our growth as we build upon the success of the Syn-One Test."
  • Founded in 2017, CND Life Sciences is dedicated to supporting the care of patients facing the potential diagnosis of a neurodegenerative disease and other neurological conditions.